Australia · Research
Data-driven cognitive composites track Aβ-related decline and predict MCI: ADOPIC study
Composites derived by principal component analysis from 1,964 cognitively unimpaired adults in the ADOPIC study performed comparably to the ADCS-PACC in longitudinal sensitivity, and all predicted progression to mild cognitive impairment.

Background
Cognitive composites are expected to detect amyloid beta (Aβ)‑related decline more sensitively than individual tests1. Researchers developed and validated data‑driven composites from the harmonized ADOPIC study, which tracks the onset and progression of Alzheimer's dementia across international cohorts1.
Methods
- The study enrolled 1,964 cognitively unimpaired participants at baseline, with 1,110 of them having longitudinal follow‑up1.
- Domain‑specific and general composites were created using principal component analysis1.
- They were evaluated for psychometric properties, sensitivity to (Aβ)‑related decline, and prediction of mild cognitive impairment, in comparison with the ADCS‑PACC1.
Results
- Psychometric properties ranged from good to excellent, and the composites separated Aβ trajectories in CU participants (p < 0.001)1.
- General cognition showed longitudinal sensitivity comparable to the ADCS‑PACC (d = -0.20) and similar classification accuracy, with an area under the receiver operating characteristic curve of 0.701.
- All composites significantly predicted progression to mild cognitive impairment (p < 0.001)1.
Interpretation
The authors report that the composites perform comparably to the ADCS‑PACC in longitudinal sensitivity, while also offering comprehensive psychometric characterization and domain‑specific measurement1. They view this as support for using these composites as outcome measures in preclinical Alzheimer's disease research1.
References
- Tallapragada B, Galna B, Shishegar R, Markovic SJ, Brown BM, Dore V, et al. Data‑driven cognitive composites predict Aβ‑related decline and progression to MCI: the ADOPIC study. Alzheimers Dement. 2026;22(10):e71917. doi:10.1002/alz.71917. PMID: 42860384. PubMed
